Dr Reddys Laboratories launches OTC Lansoprazole delayed release capsules

21 May 2012 Evaluate

Dr Reddys Laboratories has launched over the counter (OTC) Lansoprazole delayed release capsules in the US market following the company’s ANDA approval by United States Food & Drug Administration (USFDA).

The company will make the product under store brand lables in the US market. The product is the bioequivalent version of Novartis Consumer Health’s Prevacid 24 HR capsules which received Rx-to-OTC switch approval with 3 year exclusivity from the FGDA on March 18, 2009.

Recently, the company launched Clopidogrel Tablets, USP 75mg and 300mg, a bioequivalent generic version of Plavix in the US market. The ANDAs for Clopidogrel Tablets USP 75mg and 300mg are approved by the United States Food & Drug Administration (USFDA). 

The company registered a growth of 27.68% in fourth quarter ended March 31, 2012 net profit at Rs 211.79 crore as compared to Rs 165.87 crore for the quarter ended March 31, 2011. Total income increased by 49.09% to Rs 2051.18 crore January-March quarter, 2012 from Rs 1375.77 crore for the similar quarter a period ago.

Dr. Reddys Lab Share Price

1341.60 -0.85 (-0.06%)
23-Dec-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1341.60
Cipla 1476.45
Lupin 2168.25
Zydus Lifesciences 972.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.